Lockton launches Professional and Executive Risk, transforming its global financial lines business

Lockton, the world's largest independent insurance brokerage, has announced today the unification of its U.S.-based Lockton Financial Services (LFS) and International ProFin teams under a single, global practice: Lockton Professional and Executive Risk. https://mma.prnewswire.com/media/2342384/Lockton_70_mm_Black_Logo.jpg This strategic integration brings together the expertise of more than 750 talented Associates worldwide into a single platform designed to further […]

The Vistria Group’s Real Estate Debut Exceeds $2.5 Billion AUM in Two Years

Vistria Housing Fund, LP Portfolio Now Exceeds 7,000 Units Nationwide The Vistria Group, LP (“Vistria”), a private investment firm that seeks to deliver both superior financial returns and meaningful impact, announced that its real estate strategy has exceeded $2.5 billion of assets under management (“AUM”), making it one of the fastest growing recent real estate

Rural King Brings Farm and Home Essentials to Jasper with New Store

Rural King, a family-owned retailer dedicated to the rural lifestyle, is excited to announce that its newest store in Jasper, Ala. is now open. https://mma.prnewswire.com/media/2322663/Rural_King_Logo_Logo.jpg Grand opening festivities will take place from Friday, April 4 through Sunday, April 6, featuring Rudy Special deals, and incredible prices on many items throughout the store. RK Rewards loyalty

Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R Agonist

Ultra-long-acting subcutaneous (SQ) injection formulation of small molecule ASC30 demonstrated a 36-day half-life in patients with obesity, supporting once monthly or less frequent administration. -As previously disclosed, oral tablet formulation of small molecule ASC30 demonstrated potentially best-in-class 6.3% weight loss in patients with obesity after a four-week treatment. Ascletis Pharma Inc. (HKEX:1672, “Ascletis”) today announces

Aclarion Provides Update on Strength of Company Positioning Following Q1 Strategic Initiatives

(NASDAQ:ACON),(NASDAQ:ACONW), Over $20M raised in Q1 with nearly $15M cash on hand No debt, no preferred equity, and no warrants with strike prices near the current market Nasdaq compliant: fully meets bid price and shareholder equity requirements Pivotal CLARITY trial fully funded with initial interim results expected in Q2 2026 BROOMFIELD, Colo., March 31, 2025

Village Farms International Welcomes Yvonne Trupiano as Global Chief Human Resources Officer

(NASDAQ:VFF), – Former consumer goods distribution, food, and retail service industry executive will help guide the Company's global expansion initiatives – VANCOUVER, British Columbia, March 31, 2025 (GLOBE NEWSWIRE) — Village Farms International, Inc. (“Village Farms” or the “Company”) (NASDAQ: VFF) today announced the hiring of Yvonne Trupiano as the Company's Executive Vice President and

Kaspi.kz: Announcement of AGM Results

(NASDAQ:KSPI), ALMATY, Kazakhstan, March 31, 2025 (GLOBE NEWSWIRE) — Joint Stock Company Kaspi.kz (Nasdaq: KSPI) announces that the following resolutions were duly passed at its Annual General Meeting on 28 March 2025: To approve the agenda of the Annual General Meeting of Shareholders of JSC Kaspi.kz: Approval of the agenda; Approval of JSC Kaspi.kz's 2024

LM Funding America, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

(NASDAQ:LMFA), – Fourth quarter and full-year 2024 total revenue of $2.0 million and $11.0 million, respectively.– Fourth quarter and full-year 2024 CORE EBITDA of $3.3 million and $3.9 million, respectively.– Held 165.8 Bitcoin on February 28, 2025 valued at approximately $14.4 million, as of March 26, 2025 TAMPA, Fla., March 31, 2025 (GLOBE NEWSWIRE) —

Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study

(NASDAQ:PCVX), — At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20(R) (PCV20) — — At All Doses Evaluated, VAX-24 Elicited Substantial Immune Responses Following Primary Three-Dose Immunization Series; Topline Results Also Include Interim Booster Dose IgG Data Showing Robust Memory Responses Across All Doses — —

Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update

(NASDAQ:UNCY), – Oxylanthanum carbonate (OLC) New Drug Application for hyperphosphatemia in chronic kidney disease patients on dialysis under review by the FDA with a PDUFA target action date of June 28, 2025 – Commercial planning in preparation for anticipated commercial launch of OLC in late 2025 LOS ALTOS, Calif., March 31, 2025 (GLOBE NEWSWIRE) —

Scroll to Top